Payment overview · 2025
General Payments
$171.72
9 reported records · 6 companies
Healthcare provider profile · identity verified
Alex Joseph Blanco, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAREDO, TX · NPI 1962573055
Verified facts
What the public records show
CMS Open Payments records show Alex Joseph Blanco, MD received $171.72 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.38 | 31.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.79 | 27.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.84 | 13.3% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.81 | 11.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $15.16 | 8.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.74 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $171.72 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $53.38 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $53.38 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 457 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 85 |
| Metformin Hcl | Metformin Hcl | 314 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 83 |
| Omeprazole | Omeprazole | 250 | 59 |
| Ozempic | Semaglutide | 240 | 41 |
| Montelukast Sodium | Montelukast Sodium | 219 | 71 |
| Losartan Potassium | Losartan Potassium | 206 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 31 |
| Farxiga | Dapagliflozin Propanediol | 159 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 51 |
| Gabapentin | Gabapentin | 126 | 35 |
| Alendronate Sodium | Alendronate Sodium | 121 | 42 |
| Sertraline Hcl | Sertraline Hcl | 121 | 25 |
| Lisinopril | Lisinopril | 114 | 31 |
| Alprazolam | Alprazolam | 113 | 26 |
| Nifedipine Er | Nifedipine | 113 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 42 |
| Carvedilol | Carvedilol | 107 | 36 |
| Enalapril Maleate | Enalapril Maleate | 107 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 103 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 38 |
| Pregabalin | Pregabalin | 102 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 26 |
| Donepezil Hcl | Donepezil Hcl | 86 | 25 |
| Tramadol Hcl | Tramadol Hcl | 81 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 22 |
| Ibuprofen | Ibuprofen | 75 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 25 |
| Ezetimibe | Ezetimibe | 72 | 31 |
| Meloxicam | Meloxicam | 72 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 19 |
| Januvia | Sitagliptin Phosphate | 70 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 15 |
| Eliquis | Apixaban | 68 | 11 |
| Chlorthalidone | Chlorthalidone | 66 | 19 |
| Furosemide | Furosemide | 64 | 23 |
| Metformin Hcl Er | Metformin Hcl | 64 | 13 |
| Meclizine Hcl | Meclizine Hcl | 63 | 22 |
| Mounjaro | Tirzepatide | 63 | 12 |
| Famotidine | Famotidine | 62 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 17 |
| Jardiance | Empagliflozin | 56 | 17 |
| Linzess | Linaclotide | 54 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 28 |
| Clonazepam | Clonazepam | 50 | 11 |
| Simvastatin | Simvastatin | 48 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 11 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 20 |
| Irbesartan | Irbesartan | 39 | 11 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 14 |
| Finasteride | Finasteride | 35 | 11 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Naproxen | Naproxen | 32 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 30 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Valsartan | Valsartan | 28 | 11 |
| Azithromycin | Azithromycin | 27 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Baclofen | Baclofen | 24 | 13 |
| Clotrimazole | Clotrimazole | 24 | 16 |
| Digoxin | Digoxin | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Trulance | Plecanatide | 20 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 13 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 12 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Segluromet | Ertugliflozin/Metformin | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $171.72 · 9 records | Amgen Inc. | CAPVAXIVE, GARDASIL 9, MOUNJARO, OTEZLA, PURIFIED CORTROPHIN GEL, REPATHA, REXULTI, Tymlos, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error